Literature DB >> 12728654

[Mortality and tuberculosis: analysis of multiple causes in the Community of Madrid (1991-1998)].

María Ordobás1, Ana Gandarillas, Karoline Fernández de la Hoz, Silvia Fernández Rodríguez.   

Abstract

BACKGROUND: Mortality from tuberculosis (TBC) is of characteristics such as to be studied with a multiple cause focus, as this disease is not generally fatal in itself, but is however linked to many deaths. This study is aimed at describing TBC as a cause of death in the Autonomous Community of Madrid throughout the 1991-1998 period.
METHOD: A descriptive study of deaths in the Autonomous Community of Madrid (1991-1998) entailing TBC as the main cause or as a diagnosis mentioned in the Death Statistics Bulletin (DSB). The data was taken from the Autonomous Community of Madrid Death Registry. Variables analyzed: sex, age, year deceased, main cause and other diagnoses mentioned in the DSB. Crude annual rates, standardized rates by age and specific rates by age and sex were calculated. A comparison was made as to the average number of diagnoses per death.
RESULTS: A total of 1,206 deaths "with TBC", 915 males and 291 females, were recorded. The main cause was TBC in 566 of these cases, HIV/AIDS in 442 and other diseases in 198 cases. The "with TBC" death rates showed peak values in 1995 among both males and females. There were an average of 3.4 diagnoses per death, this average having undergone an increase throughout the period under study (p < 0.05)
CONCLUSIONS: With a multi-cause focus, TBC doubles in death rate statistics. Its presence is associated with other diseases, especially with HIV/AIDS for the period analyzed.

Entities:  

Mesh:

Year:  2003        PMID: 12728654

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  1 in total

1.  Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment.

Authors:  T Rodrigo; M Casals; J A Caminero; J M García-García; M A Jiménez-Fuentes; J F Medina; J P Millet; J Ruiz-Manzano; J Caylá
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.